Toxicity and adverse effects of everolimus in the treatment of advanced nonsmall cell lung cancer pretreated with chemotherapy‑Chinese experiences.
Indian J Cancer
;
2015 Nov; 52(5)Suppl_1: s32-s36
Article
in English
| IMSEAR
| ID: sea-169220
ABSTRACT
BACKGROUND:
There is not more treatment selection for advanced nonsmall‑cell lung cancer (NSCLC) patients who had disease progression after two previous treatments. Everolimus is an oral inhibitor of the mammalian target of rapamycin pathway, which is aberrantly activated in NSCLC. PATIENTS ANDMETHODS:
Stage IV NSCLC patients, with one or multiple prior chemotherapy regimens, received everolimus 5–10 mg/day with or without chemotherapy until progression or unacceptable toxicity. The primary objective were toxicity of everolimus and overall disease control rate (DCR).RESULTS:
22 patients were enrolled. Common ≥grade3 events were stomatitis, dyspnea, vomiting, thrombocytopenia. Overall disease control rate was 54.5% among 22 patients, 1 had a partial response, and 11 had disease stabilization. Common ≥Grade 3 events were stomatitis, dyspnea, vomiting, and thrombocytopenia.CONCLUSION:
Everolimus was well tolerated, showing the modest clinical activity in heavily pretreated advanced NSCLC.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Language:
English
Journal:
Indian J Cancer
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS